{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/insulin-therapy-in-type-2-diabetes/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"bc06b7e7-e2fe-54d4-88af-3eb1d924ea47","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 7628abad-c73e-4381-8206-3780bed77334 --><h2>Changes</h2><!-- end field 7628abad-c73e-4381-8206-3780bed77334 -->","summary":null,"htmlStringContent":"<!-- begin item 5d434969-90c2-415f-9933-a070d05fc2ae --><!-- begin field bce8b710-184d-4a54-89a3-638c171dc444 --><p><strong>January 2021 </strong>— reviewed. A literature search was conducted in November 2020 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone minor restructuring to improve clarity and navigation. The recommendations have been updated in line with current literature.</p><!-- end field bce8b710-184d-4a54-89a3-638c171dc444 --><!-- end item 5d434969-90c2-415f-9933-a070d05fc2ae -->","topic":{"id":"67fc9a6c-6820-57fe-9097-e58e4a920884","topicId":"88119743-0abc-4e8b-8f25-e4fc3f538484","topicName":"Insulin therapy in type 2 diabetes","slug":"insulin-therapy-in-type-2-diabetes","lastRevised":"Last revised in January 2021","chapters":[{"id":"4f9882ba-20c0-5e9e-bb3a-2155b58e9fa3","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"389303c3-3ee2-5555-ae0c-a591f93d77cc","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"514165fe-0c20-5522-a4e0-11c24b147228","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"bc06b7e7-e2fe-54d4-88af-3eb1d924ea47","slug":"changes","fullItemName":"Changes"},{"id":"ef37d0a0-9664-5b62-b330-ad962b4b3a68","slug":"update","fullItemName":"Update"}]},{"id":"a5f3d9b7-224a-5eea-989b-9a0cbacf5225","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f2bce4cb-bcce-5ce9-996d-2ced6ac3a50a","slug":"goals","fullItemName":"Goals"},{"id":"6455faf7-803e-54c2-8dd1-2cbbd74a5d85","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cf13482a-90e2-55e5-9af9-b7d5293d52ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"3d065be5-2b02-510f-9371-5b67f3ccc4a3","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"bd7fd90b-c79f-59b8-9faf-deb57545cee3","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d6ece006-e4c1-51be-bb8b-c25c0677c4ca","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"43e27bd2-a6b7-552a-b13d-c83d6f3d0236","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"578c4a95-b0c0-57ab-9331-874d0bc55f06","slug":"what-is-insulin","fullItemName":"What is insulin?"}]},{"id":"8cb52e25-e560-555c-9e28-b8aa54455a25","fullItemName":"Management","slug":"management","subChapters":[{"id":"e1e64ce2-2b3e-5b6c-81d3-e0bb4541d132","slug":"insulin-therapy-type-2-diabetes","fullItemName":"Scenario: Insulin therapy - type 2 diabetes"}]},{"id":"52a8abf6-b1aa-55a4-b678-dec7383f5683","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"0589e653-130e-5d79-9918-c4d6981bca94","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0274003c-a029-5e95-add6-16cb7afbee51","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"43dcfc3e-f5f4-5f31-b9cf-8af2f3f255be","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8ace3fa1-6c91-5ca6-b45a-a561f03342a4","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"1a572d4a-4179-5fbe-8d18-4a37c55e2078","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ed27f179-49b6-5ae8-a5bf-c2d6fdc0cb4c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"11154307-c719-57fb-8971-db931a520f7c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"514165fe-0c20-5522-a4e0-11c24b147228","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"5e4f2864-e8d6-5de5-bd50-0b75fcbb7fdb","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 6c956ca4-9ba4-44ff-be08-59398ad4e733 --><h3>Previous changes</h3><!-- end field 6c956ca4-9ba4-44ff-be08-59398ad4e733 -->","summary":null,"htmlStringContent":"<!-- begin item 3159c1ca-683b-4395-b41b-9e4ea68cd6c3 --><!-- begin field f74f9447-bebf-4e39-a515-fa1fa1cf802a --><p><strong>July 2016</strong> — reviewed. A literature search was conducted in April 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The recommendations have been updated in line with recommendations in the National Institute for Health and Care Excellence (NICE) guidelines <em>Type 2 diabetes in adults: management (2015)</em> and <em>Diabetes (type 1 and type 2) in children and young people: diagnosis and management (2015)</em>.</p><p><strong>August 2014</strong> — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a medical device alert stating that Accu-Chek Compact<sup>®</sup>, Accu-Chek Mobile<sup>®</sup>, and Accu-Chek Active<sup>®</sup> devices and test strips may give falsely low blood glucose readings in people receiving ceftriaxone therapy.</p><p><strong>July 2013 </strong>—<strong> </strong>minor update. Links to the DVLA website have been updated.</p><p><strong>March 2013 </strong>—<strong> </strong>minor update. The telephone number for NHS Direct has been updated.</p><p><strong>March 2012 </strong>—<strong> </strong>minor update. Links to local policies on when to initiate changes in insulin doses have been updated. Issued in April 2012.</p><p><strong>February 2012 </strong>—<strong> </strong>minor update. Information from the guideline <em>Recognition, treatment and prevention of hypoglycaemia in the community (2011) </em>commissioned by NHS Diabetes has been added to the text. Issued in April 2012.</p><p><strong>November 2011 </strong>—<strong> </strong>minor update. Information on fitness to drive from the DVLA <em>At a glance guide to the current medical standards of fitness to drive </em>has been added. Sanofi is to phase out Optiset<sup>®</sup>, Opticlick<sup>®</sup>, and Optipen<sup>®</sup>devices by December 2011; information on these devices has been removed from this CKS topic. Issued in December 2011.</p><p><strong>May 2011 </strong>—<strong> </strong>minor update. A section on <em>Insulin passports </em>has been added to the <em>Prescribing information </em>section following the National Patient Safety Agency patient safety alert on safer use of insulin. Issued in June 2011.</p><p><strong>March 2011 </strong>—<strong> </strong>minor update. By 31st March 2011, Humalog and Humulin pre-filled pens will be available only as the KwikPen<sup>®</sup>. Older pre-filled pen devices for these insulins have been discontinued. Issued in March 2011.</p><p><strong>November 2010 </strong>—<strong> </strong>minor update. Minor text amendments made. Issued in November 2010.</p><p><strong>July to November 2010 </strong>—<strong> </strong>this is a new CKS topic. The evidence base has been reviewed in detail, and recommendations are clearly justified and transparently linked to the supporting evidence.</p><!-- end field f74f9447-bebf-4e39-a515-fa1fa1cf802a --><!-- end item 3159c1ca-683b-4395-b41b-9e4ea68cd6c3 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}